One in two people will develop some form of cancer in their lifetimes. Despite decades of work, one-sixth of worldwide deaths are due to cancer. High-stakes research underpinned by strong alliances are making possible new therapies, bringing ne

Meet the BTD Team: Mike Princi, Managing Consultant

Dec 3rd, 2021 32m 3s

Mike Princi joined the BTD team as a Managing Consultant in 2020 and brings deep experience in advising and leading transformation programmes within complex, international environments. Mike draws upon his military background and eclectic exper

Meet the BTD Team: David Olsson, UK Partner

Nov 3rd, 2021 32m 41s

A Partner at Beyond the Deal, David Olsson joined the BTD team five years ago having spent time in Market Development and Integration in both corporate and PE-owned firms. Among many other things, David leads our relationships and support of ou

Meet the BTD Team: Louise Cooper, Managing Consultant

Oct 25th, 2021 29m 44s

A senior project, programme and integration professional, Louise Cooper joined the BTD team several years ago and has supported some of our largest and most complex engagements with clients such as Spectris and Glatfelter. In this podcast, Loui

Targeting Those Most in Need: Access-Focused Product Partnerships at Novartis

Sep 16th, 2021 53m 14s

All pharmaceutical companies look to leverage their capabilities to benefit those in the World’s poorest countries. Novartis aims to go beyond corporate philanthropy to create a more sustainable therapy-development model. By marshalling partner

Meet the BTD Team: John Palmer, Senior Consultant

Aug 11th, 2021 18m 23s

John Palmer is a Senior Consultant who joined BTD in 2018, bringing his deep experience in business analysis and financial modelling to the team and our clients. John also leads our recruitment efforts and is pivotal in ensuring new team member

Meet the BTD Team - Barbara Vrdlovec, Director

Aug 2nd, 2021 23m 15s

Barbara Vrdlovec joined BTD over ten years ago, and as our newest Director has seen almost every aspect of the business and our client work since then, supporting clients such as bwinParty, Glatfelter, and Innogy. She also leads our relationshi

Meet the BTD Team - Nick Palmer, Partner, USA

Jul 28th, 2021 27m 39s

Introducing our newest Partner and Head of our US practice, Nick Palmer. In this podcast, Nick discusses his 35 years in consulting and his approach to creating value for clients. Nick and Carlos discuss approaches and ideas that can help execu

Back to Basics Podcast 10: Leading Integration from the Front

Mar 31st, 2021 33m 10s

Congratulations – you’re now responsible for integrating the new acquisition, and therefore delivering the benefits of the deal. You’ve been given an integration Manager and team to support you, but ultimately you’re on the hook. If we closely

Post-M&A Simplicity: Keeping IT Integration Fast, Flexible and Focussed

Mar 24th, 2021 44m 53s

For over half a century, computing power has been an integral part of business models. Whether simply managing back-office functions or actually central to the company’s business, business needs ‘IT.’For the same half century the prevailing ico

Back to Basics 9: Treating Culture Seriously, Pragmatically, and without Fear

Mar 12th, 2021 46m 38s

Culture culture blah blah. Yes, we all know it’s important for integration success, we all know it’s hard…but what impact does it really have on the ground? And more to the point, is there anything realistically that can be done about it, or is

Back to Basics 8: Resourcing Integration from within your own Business

Mar 8th, 2021 47m 37s

Having discussed what and when, an equally critical consideration is who. Some organisations will try to conduct M&A and integration entirely in-house, believing they can do it all themselves. Others will outsource most if not all of the exerci

Partner of Choice 2021: Alliance Management and M&A Combine Forces at Novartis

Feb 9th, 2021 47m 7s

Join Novartis executives Christelle Sanglier-Bornstein, Global Head of Post-Merger Integration, and Knut Sturmhoefel, Global Head of Alliance Management, as they discuss establishing Novartis as a Partner of Choice (PoC) across its portfolio of

Back to Basics 7: Managing Integration & Improvement Post-Close as a Formal Programme

Jan 22nd, 2021 28m 57s

So the deal is done and the opportunity to transform the business and add value has been created; now the hard work begins. There’s lots to be done, uncertainties are everywhere, and the pace to deliver deal benefits if anything has become fast

Back to Basics 6: Connecting all the Dots Pre-Deal to Post Close

Jan 15th, 2021 34m 11s

A nice consultancy phrase, but what does it really mean? A huge amount in this case: Designing integration specifically to deliver acquisition goals, and shaping your pre-deal process to consider integration challenges and opportunities is cent

Back to Basics 5: Full integration isn’t always the right answer!

Jan 6th, 2021 34m 44s

Just as with leaving the new acquisition alone post-close, integrating fully into your own business is also a common approach. Doing so is often seen as the easiest, best and possibly only way to achieve your acquisition goals: full integration

Back to Basics 4: Don't leave the deal alone post-close

Dec 14th, 2020 27m 6s

Leaving the new acquisition alone post-close is common and well-intentioned. After all, what’s wrong with getting to know them better first, then taking it slowly and supporting them to run their business better over time? In this, the fourth i

Back to Basics 3: Being able to Walk Away from the Deal

Dec 10th, 2020 28m 21s

Walking away from a deal happens all the time, where’s the problem? Often there isn’t one, but many also know the dangers of deal momentum first-hand. What makes walking away so difficult for some, and more importantly, is this a real problem?

Back to Basics 2: Considering all your Deal Options

Dec 1st, 2020 41m 8s

When most consider M&A, they automatically think of the most common scenario in which the acquirer buys 100% of the target business. But this isn’t your only option; in fact in many cases it’s anything but your best choice.In this, the second i

Back to Basics 1: Understanding How You Will Be a Better Owner of this Company

Dec 1st, 2020 27m 28s

Sure, everyone instinctively thinks they’ll be a better owner of their newly-acquired business, but is this really true? More importantly, do you, the acquirer, ask yourself the most important questions: What specifically will make you better?

A Great Smaller Firm is Not a Smaller Great Big Firm: Alliance and M&A Success at Upsher-Smith

Oct 27th, 2020 31m 16s

Rusty Field, CEO of Upsher-Smith Pharmaceuticals, talks to BTD Partner, Nick Palmer, and explains building and maintaining strong capabilities for delivering M&A Integration and Strategic Alliance value in a 600-person company. In this discussi

The View from 13,000 Feet: Outside Perspective on Tackling M&A and Alliances in Pharmaceuticals and Biotechnology

Oct 13th, 2020 42m 28s

The success of Alliance-Management groups in pharmaceutical and biotechnology companies has naturally led to their involvement in M&A integrations as well. At the Association of Strategic Alliances Professionals (ASAP) Bio-Pharma Conference in

Making sense of M&A: Private equity integration from a CEO's perspective

Oct 8th, 2020 20m 45s

In the first of our Making Sense of M&A series, David Olsson speaks with Katherine Ellis, CEO of Boston Multi Family Office, to discuss private equity integration from a portfolio CEO's perspective and her experience of BTD's Supported Integrat

Helping them help you: The buyer’s role in a successful separation pre-deal

Sep 30th, 2020 18m 43s

More preparation – more value! When it comes to divestments it really does pay to think like the buyer, understand their needs and wants, and reduce their risk. In this session, Carlos Keener speaks with Toby Tester, Senior consultant at BTD ab

M&A - Steps to build confidence early that an acquisition will perform in the long-term

Sep 28th, 2020 28m 37s

Love at first sight? Often that ‘perfect match’ acquisition target turns out to be less than ideal post-close: you may have thoroughly tested the opportunity, but not your ability as an acquirer to realise it. In this session, Carlos Keener spe